Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | RORB | Q92753 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990114 | 0.88 | RORC (0.48) | RORCGAARORARORB | |
| SCHEMBL21990101 | 0.80 | HPGD (0.57) | RORC | |
| SCHEMBL22043976 | 0.78 | SLC22A12 (0.50) | RORCGAA | |
| SCHEMBL20594906 | 0.78 | RORC (0.42) | RORCGAARORARORBCYP3A4 | |
| SCHEMBL17447342 | 0.75 | NOTUM (0.60) | RORCCYP3A4CYP2C19 | |
| SCHEMBL15616679 | 0.68 | RORC (0.86) | RORCRORARORB | |
| SCHEMBL21905610 | 0.68 | STING1 (0.55) | RORC | |
| SCHEMBL21990041 | 0.68 | STING1 (0.48) | RORCCYP3A4CYP2C9 | |
| SCHEMBL15616593 | 0.68 | RORC (0.65) | RORCGAARORARORB | |
| SCHEMBL22043972 | 0.67 | STING1 (0.73) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | RORC 729/4885GAA 1376/4885RORA 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.